



COMBINED REVOCATION AND POWER OF ATTORNEY AND STATEMENT UNDER 37 C.F.R. § 3.73(B)

Intarcia Therapeutics, Inc. states that it is the assignee of the entire right, title, and interest to the patent applications/patents identified below by virtue of the assignment and/or other chain of title documents recorded on the dates at the reel and frame numbers specified below:

ITI Ref No.	Dechert RefNo.	Serial No./ Patent No.	Title	Recordation Date	Reel/Frame
BMED-001/00US	375608-001USP1	60/098,341	Method for Mitigating the Adverse Effects of Interleukin-2	03/24/2000 09/09/2005 09/09/2005	010698/0311 016500/0897 016512/0152
BMED-001/01US	375608-001US	09/334,276	Method for Mitigating the Adverse Effects of Interleukin-2	03/24/2000 09/09/2005 09/09/2005	010698/0311 016500/0897 016512/0152
BMED-001/02US	375608-001T1	09/932,011 US 6,423,744	Method for Mitigating the Adverse Effects of Interleukin-2	08/16/2001 09/09/2005 09/09/2005	012101/0030 016500/0897 016512/0152
BMED-003/00US	375608-003USP1	60/238,772	Combination Therapy for the Treatment of Estrogen- Sensitive Disease	01/14/2002 01/14/2005	012519/0137 016151/0028
BMED-003/01US	375608-003US	09/970,509	Combination Therapy for the Treatment of Estrogen- Sensitive Disease	01/14/2002 01/14/2005	012519/0137 016151/0028
BMED-003/02US	375608-003C1	10/982,533	Combination Therapy for the Treatment of Estrogen- Sensitive Disease	01/14/2002 01/18/2005	012519/0137 016152/0303
BMED-003/03US	375608-003C2	10/982,697	Combination Therapy for the Treatment of Estrogen- Sensitive Disease	01/14/2002	012519/0137
BMED-003/05US	375608-003C3	11/144,915	Combination Therapy for the Treatment of Estrogen- Sensitive Disease	01/14/2002	012519/0137
BMED-003/04US	375608-003C4	11/114,932	Combination Therapy for the Treatment of Estrogen- Sensitive Disease	01/14/2002	012519/0137
BMED-004/00US	375608-004USP1	60/245,883	Method for Short-Term and Long-Term Drug Dosimetry	04/05/2002 01/04/2005	012799/0289 016126/0064
BMED-004/01US	375608-004US	10/004,118	Method for Short-Term and Long-Term Drug Dosimetry	04/05/2002 01/04/2005	012799/0289 016126/0064
BMED-004/02US	375608-004C2	10/982,532	Method for Short-Term and Long-Term Drug Dosimetry	04/05/2002 01/04/2005	012799/0289 016126/0064
BMED-004/03US	375608-004C3	10/982,398	Method for Short-Term and Long-Term Drug Dosimetry	04/05/2002 01/13/2005	12799/0289 016147/0276
BMED-006/00US	375608-006USP1	60/337,948	Method for Treating Diseases with Omega Interferon	02/19/2003 08/29/2005 01/14/2005	013755/0217 016467/0877 016150/0950
BMED-006/01US	375608-006US	10/290,790	Method for Treating Diseases with Omega Interferon	02/19/2003 08/29/2005 01/14/2005	013755/0217 016467/0877 016150/0950

ITI Ref No.	Dechert RefNo.	Serial No./ Patent No.	Title	Recordation Date	Reel/Frame
BMED-007/00US	375608-007US	10/452,324	Method of Mitigating the Adverse Effects of IL-2	10/14/2003	014048/0367
				10/14/2003	014048/0376
				09/09/2005	016512/0322
BMED-011/00US	375608-011USP1	60/680,938	Method of Treating Bone Loss	09/16/2005	016545/0380
032533-004	375608-012USP1	60/135,995	Methods of Treating Proliferative Disorder	09/13/99	010225/0704
032533-005	375608-012US	09/577,689 US 6,566,395	Methods of Treating Proliferative Disorders	05/22/2000	010816/0824
				09/09/2005	165000/0959


Assignee hereby revokes all previous powers of attorney and appoints the Dechert LLP attorneys and agents associated with Customer Number 37509 to prosecute the patent applications identified above and to transact all business in the Patent and Trademark Office connected therewith, including full power of association, substitution, and revocation.

Please address all telephone calls and correspondence to Ann M. Caviani Pease at the address corresponding to Customer Number 37509, currently:

DECHERT LLP
1117 California Avenue
Palo Alto, Ca 94304-1106
Tel: (650) 813-4800
Fax: (650) 813-4848

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Dated: 06 Oct, 2005

Signature: 
Curtis L. Scribner, M.D., M.B.A.
Vice President, Regulatory Affairs
INTARCIA THERAPEUTICS, INC.